Moderators:

• Richard Glenn Stock, MD, is employed by Icahn School of Medicine at Mount Sinai. 
• Jacqueline Esthappan Zoberi, PhD, DABR, FAAPM, is employed by Washington University School of Medicine, Department of Radiation Oncology. Dr. Zoberi is a member of the ASTRO Code Development and Valuation Subcommittee, participates in ASTRO Radiopharmaceutical workshops/webinars, and is the Co-chair of the ASTRO Safety White Paper on RPT. 
• Bridget F. Koontz, MD, FASTRO, is employed by AdventHealth Cancer Institute. Dr. Koontz sits on the Board of Directors for Rythera Therapeutics and is an Advisory Board member for Blue Earth Diagnostics, Lantheus, and Novartis. NRG Oncology receives research support from NCI, Sumitomo (GU011).

Speakers:

• Ana P. Kiess, MD, PhD, is employed by the Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine. Dr. Kiess receives clinical trial funding from Bayer, Novartis, Merck, Lantheus, and Convergent. Dr. Kiess is a volunteer consultant/speaker/advisor for Novartis, POINT, and PMH. 
• Steven Graves, PhD, DABR, is employed by the University of Iowa. Dr. Graves receives research funding from the University of Iowa, Siemens, Mirion Medical, FNIH, NCI, and Novartis. Dr. Graves receives honoraria from MTMI, Voximetry, AAPM, MIM, Spectrum Dynamis, and Mirion Medical. He consults for RayzeBio, CDE Dosimetry, Fusion Radiopharma, NMCTG LLC and is on the advisory board for Telix, Novartis, and Mirion Medical. 
• Hyun Kim, MD, is employed by Washington University School of Medicine. Dr. Kim receives research funding, speaker fees, and is a consultant for Varian. Dr. Kim also consults for Novartis. Dr. Kim has limited liability company interest with GlobalART as the Founder/CEO. 
• Neil K. Taunk, MD, MS, is employed by the University of Pennsylvania. Dr. Taunk has relationships with Boston Scientific, Varian Medical Systems, Point BioPharma (Lilly), Novartis, GE Healthcare, Telix Pharmaceuticals, GenMab Pharmaceuticals. Dr. Taunk receives research funding from Varian Medical Systems, Therapanacea AI, Basser Center for BRCA, RSNA, NIH. Dr. Taunk is a member of the following committees: CAMPEP Board of Governors, ASTRO Radiopharmaceutical Committee, American Radium Society Radiopharmaceutical Committee. 
• William Oh, MD, is employed by Icahn School of Medicine at Mount Sinai. Dr. Oh is the Chair of the National Prostate Cancer Roundtable at the American Cancer Society. Dr. Oh consults for Abbott, Astra Zeneca, Cytogen, Novartis, Sumitomo, and VieCure. Dr. Oh has equity in Archetype Therapeutics, GeneDx, NTx Bio, and Previvor Care.
• Ravi Shridhar, MD, PhD, is employed by Advent Health Cancer Institute and serves as the AU Program Director for Theranostics. Dr. Shridhar is a speaker, consultant, proctor for Boston Scientific and a speaker for AstraZeneca. 
• Salma K. Jabbour, MD, FASTRO, is employed by Rutgers University. Dr. Jabbour consults for Merck Sharp & Dohme Corp, Radialogica, IMX Medical, Lantern DSMC, AstraZeneca, Beigene, Deichert LLC. Rutgers University receives research funding from Merck Sharp & Dohme Corp, NCI, Beigene, Guardant, and Adlai Nortye. 
• Michael R Folkert, MD, PhD, is employed by the University of Washington. Dr. Folkert has previously received research funding from Augmenix/Boston Scientific, as well as travel reimbursement from Varian, Inc. and Boston Scientific, Inc. Dr. Folkert serves as the Brachytherapy Representative on the U.S. Nuclear Regulatory Commission (NRC) Advisory Committee on the Medical Use of Isotopes (compensated). 

The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee and the 2024 ASTRO Annual Meeting Education and Steering Committees had control over the content of this activity. All relevant relationships have been mitigated.